Geron, GenPharm International Inc. deal

GERN received exclusive licenses to two GenPharm technologies for genetically modifying primate primordial stem (PS) cells prior to their transplantation as a potential treatment for age-related diseases.

One license covers techniques for altering the genetic makeup of PS cells, which are immortal germ line cells, to enhance their therapeutic value. The second technology is a method for transferring large amounts of DNA into PS cells. ...